18/11/13

FirstWord Lists: Pharma's biggest product growth drivers: Q3 - FirstWord Pharma

Get unlimited Pharma PLUS subscriptions for one low fixed rate with a FirstWord country license. Click here for more details.

Login Subscribe Monday, November 18, 2013 Search FirstWord Pharma Archives
Search

Home

My News

All News

All Insight, Analysis and Views

StoryWatch

Channel

FirstWord Lists: Pharma's biggest product growth drivers: Q3

(Ref: FirstWord Lists) November 10th, 2013 By: Simon King

The 25 biggest year-on-year growth drivers in Q3 delivered combined absolute growth of $3.9 billion, with AbbVie's Humira and Bayer and Johnson & Johnson's Xarelto both delivering growth in excess of $400 million for the quarter year-on-year. Full-year Humira revenues are expected to breach the $10 billion threshold and the drug is widely expected to generate record breaking peak annual sales at some stage within the next five years - see ViewPoints: AbbVie's Humira accelerates towards Lipitor's crown as biggest selling pharma product of all time
(http://w w w .firstw ordpharma.com/node/1149688?tsid=33&tsid=17#axzz2kGx7H89t)

16
Me gusta

14
Share

Xarelto has continued to perform strongly since the beginning of 2013, despite the launch of Bristol-Myers Squibb and Pfizer's Eliquis, which had been widely expected to act as a brake on growth for Bayer's anticoagulant - see ViewPoints: Agree to disagree Bristol-Myers Squibb plays down once-daily dosing of Bayer's Xarelto as Eliquis continues to slow burn
(http://w w w .firstw ordpharma.com/node/1148898?tsid=33&tsid=17#axzz2kGx7H89t)

7
Tw eet

and Spotlight On: Expectations wilting for Bristol-Myers Squibb, Pfizer's Eliquis as Bayer's Xarelto goes from strength to strength
(http://w w w .firstw ordpharma.com/node/1145829? tsid=33&tsid=17&tsid=17#axzz2hd53P2QY)

www.firstwordpharma.com/node/1161566#axzz2kyX2c46Y

1/3

18/11/13

FirstWord Lists: Pharma's biggest product growth drivers: Q3 - FirstWord Pharma

A number of new launches (since mid-2012) were among the industry's biggest growing products in Q3, with this list headed by Biogen Idec's multiple sclerosis treatment Tecfidera ($268 million) - see Physician Views Poll Results: Patient warehousing for Biogen Idec's Tecfidera continues to increase among EU-based neurologists (http://w w w .firstw ordpharma.com/node/1153792?tsid=33&tsid=17#axzz2kGx7H89t) and ViewPoints: Tecfidera sales soar, but 'all or nothing' EU decision on data exclusivity looms for Biogen Idec (http://w w w .firstw ordpharma.com/node/1150342?
tsid=33&tsid=17#axzz2kGx7H89t)

Other notable inclusions include Gilead Sciences' HIV therapy Stribild ($126 million), Medivation and Astellas' prostate cancer treatment Xtandi ($109 million; see Physician Views Poll Results Medivation's Xtandi set to slot seamlessly into prechemotherapy prostate cancer market ahead of Johnson & Johnson's Zytiga, indicate urologists and oncologists (http://w w w .firstw ordpharma.com/node/1150333?
tsid=33&tsid=17#axzz2kGx7H89t)

), Celgene's myeloma treatment Pomalyst ($87 million)

and Roche's HER2 breast cancer therapy Perjeta ($85 million). The oral revolution in MS is also illustrated by the presence of Novartis' Gilenya among the quarter's top five growth drivers, while cancer therapies are prominent across the top 25. Around half of the products are biologics, with Humira, Sanofi's Lantus (diabetes) and Pfizer and Amgen's Enbrel all notable growth drivers in Q3, despite their status as relatively mature products. Notable near misses from the list include Novo Nordisk's GLP-1 agonist Victoza (see Spotlight On: Pricing pressures redefine diabetes market expectations
(http://w w w .firstw ordpharma.com/node/1153097?tsid=33&tsid=17#axzz2kGx7H89t)

) and Roche's

Kadcyla another component (alongside Perjeta) of its Herceptin life-cycle management strategy. To read more List articles, click here (/original/lists?tsid=17) . Share this Article

16
Me gusta

14
Share LinkedIn

7
Tw eet Tw eeter Email (/f orward?path=node/1161566&tsid=17) Print (/print/1161566?tsid=17)

Google

Facebook

www.firstwordpharma.com/node/1161566#axzz2kyX2c46Y

2/3

18/11/13
Related News

FirstWord Lists: Pharma's biggest product growth drivers: Q3 - FirstWord Pharma

FirstWord Lists: Pharma's biggest sales growth drivers (/node/1029803?tsid=17) FirstWord Lists: The pharma industrys top 25 product growth drivers H1 2013
(/node/1130741?tsid=17)

FirstWord Lists: The 20 biggest growing pharma products in 2012 - Sanofi's Lantus leads the way (/node/1056867?tsid=17) FirstWord Lists: The largest product growth drivers: H1 2012 (/node/1010778?tsid=17) FirstWord Lists: The largest product growth drivers: H1 2012 (/node/1010246?tsid=17)

Reference Articles
ViewPoints: AbbVie's Humira accelerates towards Lipitor's crown as biggest selling pharma product of all time (http://www.firstwordpharma.com/node/1149688?
tsid=33&tsid=17#axzz2kGx7H89t) -

(FirstWord Lists)

Search FirstWord Pharma Archives

Search

www.firstwordpharma.com/node/1161566#axzz2kyX2c46Y

3/3